New device could cut stroke risk in kidney patients on dialysis
NCT ID NCT07257614
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tests a procedure called left atrial appendage occlusion (LAAO) using the Watchman Flx PRO device in 40 dialysis patients with atrial fibrillation. The goal is to see if it safely reduces stroke and major bleeding compared to standard care. Participants will be followed for one year to track outcomes like stroke, bleeding, and device success.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Watchman Flx PRO device
What this could lead to
If successful, this could offer a safer stroke prevention option for dialysis patients with atrial fibrillation, reducing bleeding risks compared to standard blood thinners.
What could go wrong
This is a small pilot study with only 40 participants, so results may not apply broadly. The procedure carries risks like bleeding or device complications, and long-term benefits are unproven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Chinese Universityy of Hong Kong
Shatin, New Territories, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••